A New Jersey federal judge has tossed a qui tam lawsuit accusing Bayer Corp. and Johnson & Johnson of defrauding federal insurance programs through antibiotic labeling shortfalls, ruling that the complaints need more specifics in order to advance, according to Law360. 4 April 2022
The trade association representing the Belgian pharmaceutical industry has urged authorities to resume discussions on forging “a new pact,” a goal originally outlined as part of the federal coalition agreement of 30 September, 2020. 4 April 2022
Orient EuroPharma has signed a deal with the US branded and generic drugmaker Currax Pharmaceuticals to bring the weight control drug Contrave (naltrexone/bupropion) to the Taiwan market as soon as in the second half of 2022. 1 April 2022
Japanese drugmaker Daiichi Sankyo has transferred its marketing authorization of the synthetic broad spectrum antibacterial agent Cravit Tablets/Injection (levofloxacin) in China to YaoPharma. 31 March 2022
Indian drug major Sun Pharmaceutical Industries has entered into an exclusive patent licensing agreement with Danish CNS specialist Lundbeck to market and distribute its own version of vortioxetine in India. 30 March 2022
The Journal of Clinical Endocrinology & Metabolism has published positive results from the Phase III LINC 4 study of Recordati’s Isturisa (osilodrostat) in patients with Cushing’s disease. 29 March 2022
The Cystic Fibrosis Foundation announced an award for up to $15.9 million in additional funding to USA-based Eloxx Pharmaceuticals to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations, with the news lifting the firm’s shares by 8.5% to $0.52 by mid-day trading. 29 March 2022
Santhera Pharmaceuticals and ReveraGen BioPharma have started a rolling new drug application submission for vamorolone in the USA, after a successful pre-NDA meeting in late 2021. 29 March 2022
Eagle Pharmaceuticals is to buy British company Acacia Pharma, in a deal which values the firm at around $103 million, with Acacia stockholders due to receive around $0.75 in cash and 0.0049 of Eagle stock per share. 28 March 2022
Taiwan drug maker Bora Pharmaceuticals has signed a distribution deal with its Hong Kong-based counterpart Bright Future to supply the extended release (ER) combo drug Numient (carbidopa/levodopa) to treat Parkinson's disease in China, including Hong Kong and Macau. 18 March 2022
Swiss firm Santhera Pharmaceuticals and its US development partner ReveraGen BioPharma are presenting new efficacy and tolerability data for vamorolone in Duchenne muscular dystrophy (DMD). 15 March 2022
Etcembly today announced the appointment of Scott Cuthill as chief business officer (CBO). The Oxford, UK-based based company is harnessing the power of the adaptive immune system to transform the precision, scale and speed of development of TCR immunotherapies. 15 March 2022
Everest Medicines has entered into a license agreement with Swedish firm Calliditas Therapeutics to develop and commercialize Nefecon (budesonide) for the treatment of primary IgA nephropathy (IgAN) in South Korea. 14 March 2022
Bayer on Friday day announced the appointment of Michael Parrish to the position of vice president of public affairs, science and sustainability, USA. 7 March 2022
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted rezafungin, a once-weekly echinocandin, Promising Innovative Medicine (PIM) designation for the treatment of invasive candidiasis. 4 March 2022
The USA’s Institute for Clinical and Economic Review (ICER) announced that it will assess the comparative clinical effectiveness and value of four weight management products. 4 March 2022
The Pharmacosmos Group, a Danish producer of IV iron for medical use, and Kedrion Biopharma, an Italy-based specialist in the production and distribution of plasma-derived medicinal products, have announced a collaboration. 3 March 2022
French ophthalmology company Nicox has announced positive results in a Chinese Phase III trial of Zerviate (cetirizine), run by its Chinese partner, Ocumension Therapeutics. 1 March 2022
UK pharma major GlaxoSmithKline today announced that, further to the voluntary pause shared on February 18, the company has decided to stop enrolment and vaccination in trials evaluating its potential respiratory syncytial virus (RSV) maternal vaccine candidate in pregnant women (NCT04605159, NCT04980391, NCT05229068). 28 February 2022
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024